Susan Browne, PhD
Affiliations: | Merck Research Laboratories, West Point, Pennsylvania, Lansdale, PA, United States |
Google:
"Susan Browne"Mean distance: 17.48 (cluster 28)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hyson HC, Kieburtz K, et al. (2010) Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1924-8 |
| Browne SE. (2008) Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Annals of the New York Academy of Sciences. 1147: 358-82 |
| Constantinescu R, McDermott MP, Dicenzo R, et al. (2007) A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone). Journal of Clinical Pharmacology. 47: 1580-6 |
| Kim YS, Choi DH, Block ML, et al. (2007) A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 179-87 |
| Browne SE, Beal MF. (2006) Oxidative damage in Huntington's disease pathogenesis. Antioxidants & Redox Signaling. 8: 2061-73 |
| Saydoff JA, Garcia RA, Browne SE, et al. (2006) Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiology of Disease. 24: 455-65 |
| Browne SE, Yang L, DiMauro JP, et al. (2006) Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiology of Disease. 22: 599-610 |
| Kim SY, Marekov L, Bubber P, et al. (2005) Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain. Neurochemical Research. 30: 1245-55 |
| Gardian G, Browne SE, Choi DK, et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. The Journal of Biological Chemistry. 280: 556-63 |
| DiMauro JP, Yang L, Fuller SW, et al. (2005) Metabolic abnormalities precede pathologic changes in the G93A SOD1 mouse model of ALS Journal of Cerebral Blood Flow & Metabolism. 25: S64-S64 |